J. Ruggles

发表

Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials

É. Hardy, Jenny Han, R. Busch, 2017, International journal of clinical practice.

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose‐timing study

C. Weyer, S. Schwartz, M. Fineman, 2004, Diabetes/metabolism research and reviews.

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.

C. Weyer, M. Fineman, J. Ruggles, 2004, Obesity research.

Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.

C. Weyer, C. Schnabel, J. Ruggles, 2005, Diabetes care.

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

Dennis D. Kim, A. Baron, M. Fineman, 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

R. Holman, Adrian F. Hernandez, H. Heerspink, 2019, Cardiovascular Diabetology.

Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.

Jenny Han, J. Ruggles, M. Trautmann, 2016, Clinical therapeutics.

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment

É. Hardy, J. Ruggles, T. Blevins, 2016, Diabetes Therapy.

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

C. Weyer, M. Fineman, J. Ruggles, 2002, Diabetes care.

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.

L. Want, C. Weyer, M. Fineman, 2002, Diabetes technology & therapeutics.

A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes

A. Hauber, Hiep Nguyen, J. Ruggles, 2016, Current medical research and opinion.

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Dennis D. Kim, C. Weyer, S. Schwartz, 2003, Diabetes care.

Exenatide once weekly improved 24‐hour glucose control and reduced glycaemic variability in metformin‐treated participants with type 2 diabetes: a randomized, placebo‐controlled trial

J. Frias, J. Ruggles, E. Klein, 2016, Diabetes, obesity & metabolism.